The Roots of Type 1 Diabetes
Diving Into Diabetes27 Marras 2024

The Roots of Type 1 Diabetes

What do we know about the developmental stages of type 1 diabetes (T1D), and how can this understanding ultimately lead to improved patient outcomes?

Our host, Dr. Alice Cheng, explores these questions with Dr. Bruce Perkins, Professor, Endocrinologist, Epidemiologist, and Clinician-Scientist in the Faculty of Medicine and the Institute for Health Policy Management and Evaluation at the University of Toronto.

Our experts kick off the discussion by identifying the key differentiators between type 1 and type 2 diabetes, before diving into the presence and involvement of autoantibodies in the development of T1D. Dr. Perkins details the stages of T1D, and explains how identification of early stages has the potential to improve patient outcomes and prevent serious illness.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

  • Direct financial relationship, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speakers’ bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. Bruce Perkins:

  • Direct financial relationship, including receipt of honoraria or in-kind compensation: Abbott, Sanofi, Insulet, Medtronic, Novo Nordisk. Membership on advisory boards or speaker’s bureaus: Abbott, Insulet, Sanofi, Novo Nordisk, Vertex. Funded grants, research, or clinical trials: Novo Nordisk, Bank of Montreal. Patents on a drug, product, or device: Boehringer Ingelheim.

MAT-CA-2401455 Nov 2024

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(26)

Timely basal insulin in T2D: A look at treatment intensification approaches in practice

Timely basal insulin in T2D: A look at treatment intensification approaches in practice

Why does the timely addition of basal insulin remain an important issue in practice, despite the increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RA) seen in recent years?Our host, Dr...

17 Kesä 202417min

New Guidelines on Hypoglycemia Management from Diabetes Canada

New Guidelines on Hypoglycemia Management from Diabetes Canada

Hypoglycemia associated with commonly used diabetes medications can be distressing and potentially lethal. What are the latest recommendations on prevention and treatment of hypoglycemia from the Diab...

21 Helmi 20248min

New Insights on Type 2 Diabetes Remission from Diabetes Canada Guidelines

New Insights on Type 2 Diabetes Remission from Diabetes Canada Guidelines

Diabetes remission is a concept that has been gaining attention as new treatments and interventions become available in the Diabetes Canada Clinical Practice Guidelines. How do we define diabetes remi...

15 Elo 202316min

Closing the Loop in the Management of Type 1 Diabetes

Closing the Loop in the Management of Type 1 Diabetes

Numerous challenges afflict patients with type 1 diabetes (T1D) throughout their disease journey. How can newer, more innovative management approaches help patients overcome these challenges?This epis...

15 Elo 202318min

The Future of CGM Use in Type 2 Diabetes

The Future of CGM Use in Type 2 Diabetes

With the abundance of various glucose monitoring technologies, how can healthcare providers guide patients with type 2 diabetes (T2D) toward the most appropriate choice?Our host, Dr. Ronald Goldenberg...

9 Kesä 202320min

Debunking Myths Around Hypoglycemia

Debunking Myths Around Hypoglycemia

Hypoglycemia is a major concern for people living with diabetes; however, there are numerous myths and misconceptions surrounding its role in diabetes management. What are the common misunderstandings...

30 Touko 202311min

Titration Investigation: Basal Insulin and Fixed-Ratio Combination Protocols

Titration Investigation: Basal Insulin and Fixed-Ratio Combination Protocols

Titration is a crucial element for individuals with diabetes taking basal insulin to achieve their glycemic targets, so how do we ensure we’re doing it optimally?Our host, Dr. Ronald Goldberg, takes a...

1 Helmi 202313min

Exploring Exercise and Type 1 Diabetes

Exploring Exercise and Type 1 Diabetes

Exercising with diabetes requires extra preparation, so how can healthcare providers best guide those living with type 1 diabetes in exercising safely to maintain a healthy lifestyle?Our host, Dr. Ron...

15 Marras 202217min

Suosittua kategoriassa Tiede

tiedekulma-podcast
rss-poliisin-mieli
docemilia
rss-mita-tulisi-tietaa
filocast-filosofian-perusteet
rss-lapsuuden-rakentajat-podcast
rss-tiedetta-vai-tarinaa
rss-lihavuudesta-podcast
sotataidon-ytimessa
radio-antro
menologeja-tutkimusmatka-vaihdevuosiin
rss-bios-podcast
rss-duodecim-lehti
rss-metsantuntijat-podcast
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita